Division of Nephrology & Hypertension, Department of Medicine, University of Utah, Salt Lake City, UT.
James D. Eason Transplant Institute, Methodist University Hospital, Memphis, TN; Division of Transplant Surgery, Department of Surgery, University of Tennessee Health Science Center, Memphis, TN.
Am J Kidney Dis. 2021 May;77(5):739-747.e1. doi: 10.1053/j.ajkd.2020.10.017. Epub 2020 Dec 14.
RATIONALE & OBJECTIVE: Transplant centers in the United States are increasingly willing to transplant kidneys from hepatitis C virus (HCV)-infected (HCV) donors into HCV recipients. We studied the association between donor HCV infection status and kidney allograft function and posttransplantation allograft biopsy findings.
Retrospective cohort study.
SETTING & PARTICIPANTS: We examined 65 HCV recipients who received a kidney from a HCV donor and 59 HCV recipients who received a kidney from a HCV donor during 2018 at a single transplant center.
Predictor(s) of donor infection with HCV.
Kidney allograft function and allograft biopsy findings during the first year following transplantation.
We compared estimated glomerular filtration rate (eGFR), findings on for-cause and surveillance protocol biopsies, development of de novo donor-specific antibodies (DSAs), and patient and allograft outcomes during the first year following transplantation between recipients of HCV and HCV kidneys. We used linear regression to estimate the independent association between allograft function and HCV viremic status of the kidney donor.
The mean age of recipients was 52 ± 11 (SD) years, 43% were female, 19% and 80% of recipients were White and Black, respectively. Baseline characteristics were similar between the HCV and HCV groups. There were no statistically significant differences between the HCV and HCV groups in delayed graft function rates (12% vs 8%, respectively); eGFRs at 3, 6, 9, and 12 months post-transplantation; proportions of patients with cellular rejection (6% vs 7%, respectively); and proportions with antibody-mediated rejection (7% vs 10%, respectively) or de novo DSAs (31% vs 20%, respectively). HCV viremic status was not associated with eGFR at 3, 6, 9, or 12 months.
Generalizability from a single-center study and small sample size was limited.
Recipients of kidneys from donors infected with HCV had similar kidney allograft function and probability of rejection in the first year after transplantation compared to those who received kidneys from donors without HCV infection.
美国的移植中心越来越愿意将丙型肝炎病毒(HCV)感染供者的肾脏移植给 HCV 受者。我们研究了供者 HCV 感染状态与肾脏移植物功能和移植后移植物活检结果之间的关系。
回顾性队列研究。
我们检查了 2018 年在一个单一移植中心接受 HCV 供者肾脏的 65 例 HCV 受者和接受 HCV 供者肾脏的 59 例 HCV 受者。
供者 HCV 感染的预测因素。
移植后第一年的肾脏移植物功能和移植后活检结果。
我们比较了 HCV 和 HCV 受者在移植后第一年的估算肾小球滤过率(eGFR)、因病因和监测方案活检的结果、新出现的供者特异性抗体(DSA)的发展以及患者和移植物的结局。我们使用线性回归来估计移植物功能与供者 HCV 病毒血症状态之间的独立关联。
受者的平均年龄为 52 ± 11(SD)岁,43%为女性,分别有 19%和 80%的受者为白人及黑人。HCV 和 HCV 组之间的基线特征相似。在延迟移植物功能发生率(分别为 12%和 8%)、移植后 3、6、9 和 12 个月的 eGFR、细胞排斥的患者比例(分别为 6%和 7%)以及抗体介导的排斥(分别为 7%和 10%)或新出现的 DSA(分别为 31%和 20%)方面,HCV 和 HCV 组之间没有统计学上的显著差异。HCV 病毒血症状态与 3、6、9 或 12 个月的 eGFR 无关。
单中心研究的推广性和样本量小受到限制。
与接受无 HCV 感染供者肾脏的受者相比,接受 HCV 感染供者肾脏的受者在移植后第一年的肾脏移植物功能和排斥概率相似。